Positive News SentimentPositive NewsNASDAQ:IMAB I-Mab (IMAB) Stock Price, News & Analysis $1.36 -0.03 (-2.16%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.20▼$1.4450-Day Range$1.36▼$1.9052-Week Range$1.16▼$3.04Volume300,487 shsAverage Volume350,799 shsMarket Capitalization$110.00 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get I-Mab alerts: Email Address I-Mab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside800.7% Upside$12.25 Price TargetShort InterestHealthy1.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.13) to ($1.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector389th out of 936 stocksPharmaceutical Preparations Industry185th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingI-Mab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageI-Mab has received no research coverage in the past 90 days.Read more about I-Mab's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.30% of the outstanding shares of I-Mab have been sold short.Short Interest Ratio / Days to CoverI-Mab has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in I-Mab has recently decreased by 2.78%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldI-Mab does not currently pay a dividend.Dividend GrowthI-Mab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMAB. Previous Next 3.3 News and Social Media Coverage News SentimentI-Mab has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for I-Mab this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IMAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added I-Mab to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, I-Mab insiders have not sold or bought any company stock.Percentage Held by Insiders22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.38% of the stock of I-Mab is held by institutions.Read more about I-Mab's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for I-Mab are expected to grow in the coming year, from ($2.13) to ($1.70) per share.Price to Book Value per Share RatioI-Mab has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About I-Mab Stock (NASDAQ:IMAB)I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Read More IMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMAB Stock News HeadlinesJuly 15, 2024 | prnewswire.comI-Mab Announces Leadership TransitionsJune 5, 2024 | prnewswire.comI-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal CancersJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…May 23, 2024 | globenewswire.comI-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024May 22, 2024 | prnewswire.comI-Mab to Participate at the Jefferies Global Healthcare ConferenceApril 30, 2024 | prnewswire.comI-MAB Filed 2023 Annual Report on Form 20-FApril 16, 2024 | msn.comOmega Therapeutics CFO Joshua Reed to departApril 12, 2024 | markets.businessinsider.comI-MAB Buy Rating Justified by Strong Leadership and Promising PipelineJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…April 5, 2024 | prnewswire.comI-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | investing.comI-Mab completes divestiture of its Shanghai unit for $80 millionApril 2, 2024 | uk.finance.yahoo.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaApril 2, 2024 | prnewswire.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaMarch 18, 2024 | finance.yahoo.comI-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 14, 2024 | finance.yahoo.comI-Mab Reports Full Year 2023 Financial Results and Business UpdateFebruary 22, 2024 | benzinga.comI-MAB Stock (NASDAQ:IMAB), Short Interest ReportFebruary 18, 2024 | seekingalpha.comI-Mab: Trading Below Net Cash With Multiple Upside OptionsFebruary 7, 2024 | marketwatch.comI-Mab to Divest Chinese Unit for Up to $80MSee More Headlines Receive IMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMAB CUSIPN/A CIK1778016 Webwww.i-mabbiopharma.com Phone86-21-6057-8000FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+750.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.67 Quick Ratio5.67 Sales & Book Value Annual Sales$3.89 million Price / Sales29.94 Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book0.49Miscellaneous Outstanding Shares80,880,000Free Float63,008,000Market Cap$116.47 million OptionableOptionable Beta1.08 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Raj Kannan (Age 60)CEO & Director Dr. Jerry WangCo-Founder & Chief Scientific OfficerMr. Skelton JosephChief Financial OfficerMr. Tianyi ZhangVice President of Investor RelationsDr. Fernando J. Salle´s Ph.D.Senior VP and Head of U.S. & EU Business DevelopmentClaire XuHead of US siteMs. Min Yin (Age 54)Senior Vice President of Operations Dr. Louie Naumovski M.D.Ph.D., Interim Chief Medical OfficerMr. Tyler EhlerSenior Director of Investor RelationsMore ExecutivesKey CompetitorsEditas MedicineNASDAQ:EDITC4 TherapeuticsNASDAQ:CCCCCryoportNASDAQ:CYRXEsperion TherapeuticsNASDAQ:ESPROrganogenesisNASDAQ:ORGOView All CompetitorsInstitutional OwnershipGSA Capital Partners LLPSold 105,498 shares on 5/3/2024Ownership: 0.536%View All Institutional Transactions IMAB Stock Analysis - Frequently Asked Questions How have IMAB shares performed this year? I-Mab's stock was trading at $1.90 at the beginning of 2024. Since then, IMAB shares have decreased by 28.4% and is now trading at $1.36. View the best growth stocks for 2024 here. When did I-Mab IPO? I-Mab (IMAB) raised $100 million in an IPO on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers. How do I buy shares of I-Mab? Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of I-Mab own? Based on aggregate information from My MarketBeat watchlists, some other companies that I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO) and Enterprise Products Partners (EPD). This page (NASDAQ:IMAB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.